Literature DB >> 3104025

Results of in vivo and in vitro studies for assessing prenatal toxicity.

D Neubert, G Blankenburg, I Chahoud, G Franz, R Herken, M Kastner, S Klug, J Kröger, R Krowke, C Lewandowski.   

Abstract

Examples of a combined approach using in vivo as well as in vitro methods for the assessment of prenatal toxicity are presented. The topics discussed include the analysis of the possible embryotoxic potential of valproic acid (VPA), female sex hormones, bis(tri-n-butyltin) oxide (TBTO), and acyclovir and the problem of supplementing in vitro systems with drug-metabolizing activity.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3104025      PMCID： PMC1474293          DOI： 10.1289/ehp.867089

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN： 0091-6765            Impact factor:   9.031


  18 in total

Review 1.  Significance of species and strain differences in pre- and perinatal toxicology.

Authors:  D Neubert; I Chahoud
Journal:  Acta Histochem Suppl       Date:  1985

2.  Benefits and limits of model systems in developmental biology and toxicology (in vitro techniques).

Authors:  D Neubert
Journal:  Prog Clin Biol Res       Date:  1985

Review 3.  Misinterpretations of results and creation of "artifacts" in studies on developmental toxicity using systems simpler than in vivo systems.

Authors:  D Neubert; G Blankenburg; C Lewandowski; S Klug
Journal:  Prog Clin Biol Res       Date:  1985

4.  Effect of thalidomide-derivatives on limb development in culture.

Authors:  D Neubert; R Krowke
Journal:  Prog Clin Biol Res       Date:  1983

Review 5.  The use of culture techniques in studies on prenatal toxicity.

Authors:  D Neubert
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

6.  Toxicity studies with cellular models of differentiation.

Authors:  D Neubert
Journal:  Xenobiotica       Date:  1985 Aug-Sep       Impact factor: 1.908

7.  Significance of organ culture techniques for evaluation of prenatal toxicity.

Authors:  H J Barrach; D Neubert
Journal:  Arch Toxicol       Date:  1980-09       Impact factor: 5.153

8.  Preclinical toxicology studies with acyclovir: teratologic, reproductive and neonatal tests.

Authors:  H L Moore; G M Szczech; D E Rodwell; R W Kapp; P de Miranda; W E Tucker
Journal:  Fundam Appl Toxicol       Date:  1983 Nov-Dec

9.  Cardiovascular birth defects and antenatal exposure to female sex hormones: a reevaluation of some base data.

Authors:  R A Wiseman; I C Dodds-Smith
Journal:  Teratology       Date:  1984-12

Review 10.  Congenital abnormalities and hormones during pregnancy: a clinical review.

Authors:  J L Schardein
Journal:  Teratology       Date:  1980-12
View more
  5 in total

1.  Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus. II. Elucidation of the susceptible period and of the variability of embryonic stages.

Authors:  D Neubert; W Heger; H J Merker; K Sames; R Meister
Journal:  Arch Toxicol       Date:  1988-01       Impact factor: 5.153

2.  Activation of cyclophosphamide in mouse limb bud cultures using a reconstituted cytochrome P-450 system.

Authors:  M Kastner; G Blankenburg; T Schulz; G Schack; D Neubert
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

3.  Prenatal toxicity of acyclovir in rats.

Authors:  R Stahlmann; S Klug; C Lewandowski; G Bochert; I Chahoud; U Rahm; H J Merker; D Neubert
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

4.  Embryotoxic effects of thalidomide-derivatives in the non-human primate Callithrix jacchus. I. Effects of 3-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-dioxopiperidine (EM12) on skeletal development.

Authors:  H J Merker; W Heger; K Sames; H Stürje; D Neubert
Journal:  Arch Toxicol       Date:  1988-01       Impact factor: 5.153

5.  In vitro and in vivo studies on the prenatal toxicity of five virustatic nucleoside analogues in comparison to aciclovir.

Authors:  S Klug; C Lewandowski; H J Merker; R Stahlmann; L Wildi; D Neubert
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.